drugset / Trial / NCT00697476
Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the maximum tolerated dose, the activity and the safety profile of the combination of vorinostat and topotecan in patients with recurrent small cell lung cancer
Timeline
- Start
- 2009-01
- Primary completion
- 2009-09
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | 1.2 mg/m2 | Intravenous |
| Subject | Topotecan | Small molecule | 1.5 mg/m2 | Intravenous |
| Subject | Vorinostat | Small molecule | 300 mg | Oral |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |